ADAPTIVE BIOTECHNOLOGIES CORP (ADPT) — insider trading
Health Care · NASDAQ
ADAPTIVE BIOTECHNOLOGIES CORP (ADPT) has 55 reported SEC Form 4 insider transactions in our data, including 17 open-market sales among the most recent 55 (latest 2026-07-02).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-02 | ROBINS HARLAN S | Officer (Chief Scientific Officer) | Open-market sale | 146,889 | $22.45 | $3.30M | Form 4 |
| 2026-07-02 | ROBINS HARLAN S | Officer (Chief Scientific Officer) | Open-market sale | 239,351 | $21.74 | $5.20M | Form 4 |
| 2026-07-02 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion (derivative) | 12,637 | $0.00 | $0 | Form 4 |
| 2026-07-02 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion (derivative) | 12,600 | $0.00 | $0 | Form 4 |
| 2026-07-02 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion (derivative) | 12,626 | $0.00 | $0 | Form 4 |
| 2026-07-02 | LO FRANCIS | Officer (Chief People Officer) | Open-market sale | 44,838 | $22.59 | $1.01M | Form 4 |
| 2026-07-02 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion | 12,637 | $8.46 | $106.9K | Form 4 |
| 2026-07-02 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion | 12,600 | $12.14 | $153.0K | Form 4 |
| 2026-07-02 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion | 12,626 | $7.80 | $98.5K | Form 4 |
| 2026-07-01 | BOBULSKY SUSAN | Officer (Chief Commercial Officer, MRD) | Open-market sale | 487 | $22.00 | $10.7K | Form 4 |
| 2026-07-01 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion (derivative) | 14,064 | $0.00 | $0 | Form 4 |
| 2026-07-01 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion (derivative) | 4,688 | $0.00 | $0 | Form 4 |
| 2026-07-01 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion (derivative) | 12,206 | $0.00 | $0 | Form 4 |
| 2026-07-01 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion (derivative) | 3,300 | $0.00 | $0 | Form 4 |
| 2026-07-01 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion (derivative) | 3,500 | $0.00 | $0 | Form 4 |
| 2026-07-01 | LO FRANCIS | Officer (Chief People Officer) | Open-market sale | 42,261 | $22.50 | $950.9K | Form 4 |
| 2026-07-01 | LO FRANCIS | Officer (Chief People Officer) | Open-market sale | 8,743 | $22.18 | $193.9K | Form 4 |
| 2026-07-01 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion | 14,064 | $8.12 | $114.2K | Form 4 |
| 2026-07-01 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion | 4,688 | $3.99 | $18.7K | Form 4 |
| 2026-07-01 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion | 12,206 | $8.46 | $103.3K | Form 4 |
| 2026-07-01 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion | 3,300 | $12.14 | $40.1K | Form 4 |
| 2026-07-01 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion | 3,500 | $7.80 | $27.3K | Form 4 |
| 2026-06-29 | BENZENO SHARON | Officer (Chief Commercial Ofc Imm Med) | Option exercise / conversion (derivative) | 51,570 | $0.00 | $0 | Form 4 |
| 2026-06-29 | BENZENO SHARON | Officer (Chief Commercial Ofc Imm Med) | Option exercise / conversion (derivative) | 24,944 | $0.00 | $0 | Form 4 |
| 2026-06-29 | BENZENO SHARON | Officer (Chief Commercial Ofc Imm Med) | Option exercise / conversion (derivative) | 24,944 | $0.00 | $0 | Form 4 |
| 2026-06-29 | BENZENO SHARON | Officer (Chief Commercial Ofc Imm Med) | Option exercise / conversion (derivative) | 1,837 | $0.00 | $0 | Form 4 |
| 2026-06-29 | BENZENO SHARON | Officer (Chief Commercial Ofc Imm Med) | Open-market sale | 154,768 | $21.14 | $3.27M | Form 4 |
| 2026-06-29 | BENZENO SHARON | Officer (Chief Commercial Ofc Imm Med) | Option exercise / conversion | 51,570 | $8.12 | $418.7K | Form 4 |
| 2026-06-29 | BENZENO SHARON | Officer (Chief Commercial Ofc Imm Med) | Option exercise / conversion | 24,944 | $3.99 | $99.5K | Form 4 |
| 2026-06-29 | BENZENO SHARON | Officer (Chief Commercial Ofc Imm Med) | Option exercise / conversion | 24,944 | $8.46 | $211.0K | Form 4 |
| 2026-06-29 | BENZENO SHARON | Officer (Chief Commercial Ofc Imm Med) | Option exercise / conversion | 1,837 | $12.14 | $22.3K | Form 4 |
| 2026-06-26 | BENZENO SHARON | Officer (Chief Commercial Ofc Imm Med) | Option exercise / conversion (derivative) | 11,034 | $0.00 | $0 | Form 4 |
| 2026-06-26 | BENZENO SHARON | Officer (Chief Commercial Ofc Imm Med) | Open-market sale | 11,034 | $21.00 | $231.7K | Form 4 |
| 2026-06-26 | BENZENO SHARON | Officer (Chief Commercial Ofc Imm Med) | Option exercise / conversion | 11,034 | $12.14 | $134.0K | Form 4 |
| 2026-06-25 | GRIFFIN MICHELLE RENEE | Director | Option exercise / conversion (derivative) | 52,084 | $0.00 | $0 | Form 4 |
| 2026-06-25 | GRIFFIN MICHELLE RENEE | Director | Open-market sale | 52,084 | $20.18 | $1.05M | Form 4 |
| 2026-06-25 | GRIFFIN MICHELLE RENEE | Director | Option exercise / conversion | 52,084 | $7.80 | $406.3K | Form 4 |
| 2026-06-25 | BOBULSKY SUSAN | Officer (Chief Commercial Officer, MRD) | Open-market sale | 5,000 | $20.50 | $102.5K | Form 4 |
| 2026-06-16 | ROBINS HARLAN S | Officer (Chief Scientific Officer) | Open-market sale | 6,160 | $18.01 | $110.9K | Form 4 |
| 2026-06-15 | ROBINS HARLAN S | Officer (Chief Scientific Officer) | Open-market sale | 100,000 | $17.37 | $1.74M | Form 4 |
| 2026-06-11 | BOBULSKY SUSAN | Officer (Chief Commercial Officer, MRD) | Open-market sale | 5,000 | $19.00 | $95.0K | Form 4 |
| 2026-06-04 | BOBULSKY SUSAN | Officer (Chief Commercial Officer, MRD) | Open-market sale | 11,000 | $18.00 | $198.0K | Form 4 |
| 2026-06-04 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion (derivative) | 9,376 | $0.00 | $0 | Form 4 |
| 2026-06-04 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion (derivative) | 2,344 | $0.00 | $0 | Form 4 |
| 2026-06-04 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion (derivative) | 2,009 | $0.00 | $0 | Form 4 |
| 2026-06-04 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion (derivative) | 5,792 | $0.00 | $0 | Form 4 |
| 2026-06-04 | LO FRANCIS | Officer (Chief People Officer) | Open-market sale | 39,741 | $17.49 | $695.1K | Form 4 |
| 2026-06-04 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion | 9,376 | $8.12 | $76.1K | Form 4 |
| 2026-06-04 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion | 2,344 | $3.99 | $9.4K | Form 4 |
| 2026-06-04 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion | 2,009 | $8.46 | $17.0K | Form 4 |
| 2026-06-04 | LO FRANCIS | Officer (Chief People Officer) | Option exercise / conversion | 5,792 | $12.14 | $70.3K | Form 4 |
| 2026-05-18 | PISKEL KYLE | Officer (Chief Financial Officer) | Open-market sale | 3,115 | $13.04 | $40.6K | Form 4 |
| 2026-04-27 | RUBINSTEIN JULIE | Officer (President and COO) | Option exercise / conversion (derivative) | 14,707 | $0.00 | $0 | Form 4 |
| 2026-04-27 | RUBINSTEIN JULIE | Officer (President and COO) | Open-market sale | 19,037 | $14.23 | $270.9K | Form 4 |
| 2026-04-27 | RUBINSTEIN JULIE | Officer (President and COO) | Option exercise / conversion | 14,707 | $8.46 | $124.4K | Form 4 |
Ask the chat about ADPT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ADAPTIVE BIOTECHNOLOGIES CORP (ADPT).
Last updated 2026-07-02 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.